ANI Pharmaceuticals (NASDAQ:ANIP) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report released on Tuesday, Benzinga reports. They currently have a $94.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q3 2024 earnings at $0.75 EPS.

A number of other equities analysts also recently issued reports on the company. Truist Financial reiterated a hold rating and set a $60.00 price target (down previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. StockNews.com cut shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, September 7th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of Moderate Buy and an average target price of $78.80.

ANI Pharmaceuticals Trading Down 1.1 %

NASDAQ:ANIP opened at $60.38 on Tuesday. The firm has a fifty day simple moving average of $61.14 and a two-hundred day simple moving average of $63.76. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of 37.74 and a beta of 0.71. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. During the same period last year, the business posted $1.06 EPS. The firm’s revenue for the quarter was up 18.5% compared to the same quarter last year. Analysts expect that ANI Pharmaceuticals will post 3.5 EPS for the current fiscal year.

Insider Activity

In other news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the completion of the transaction, the senior vice president now directly owns 193,226 shares in the company, valued at $12,258,257.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Muthusamy Shanmugam sold 11,000 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $63.38, for a total transaction of $697,180.00. Following the completion of the transaction, the chief operating officer now owns 671,620 shares of the company’s stock, valued at $42,567,275.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the completion of the transaction, the senior vice president now owns 193,226 shares in the company, valued at $12,258,257.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 46,007 shares of company stock worth $2,911,790. 12.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC raised its position in ANI Pharmaceuticals by 287.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after purchasing an additional 15,790 shares in the last quarter. Great Lakes Advisors LLC lifted its position in ANI Pharmaceuticals by 67.1% in the 4th quarter. Great Lakes Advisors LLC now owns 48,252 shares of the specialty pharmaceutical company’s stock worth $2,661,000 after buying an additional 19,378 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in ANI Pharmaceuticals by 106.9% in the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after buying an additional 10,716 shares in the last quarter. Wakefield Asset Management LLLP bought a new position in ANI Pharmaceuticals during the first quarter valued at approximately $979,000. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $600,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.